B+
Bull case
30%
Probability
Target price
$88.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
LIVN
LivaNovaCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$81.20
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+62.0
Score
AI commentary
Primary-source tone improved after earnings. The company both raised 2026 guidance and highlighted aura6000 PMA approval, while LivaNova’s own IR stock-history page shows the stock moving from a May 5, 2026 close of $57.59 to $66.26 on May 6 and $70.92 on May 7, indicating a strong positive post-print reaction. Even so, delayed analyst target revisions were not clearly available by the T+3 follow-up window and the packet has no usable analyst-target-count field, so confidence should remain moderate rather than aggressive.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06catalystQ1 beat-and-raise resets near-term expectationsHigh impact
LivaNova reported Q1 2026 revenue of $362.3M, up 14.3% reported and 11.1% constant currency, with adjusted diluted EPS of $0.98, then raised full-year 2026 revenue growth guidance to 7.0%-8.0% and adjusted diluted EPS guidance to $4.20-$4.30 while maintaining adjusted free cash flow guidance at $160M-$180M [#8-K-2026-05-06].
2026-08-06eventOSA launch milestones after aura6000 PMA approvalHigh impact
Management highlighted FDA PMA approval for the aura6000 System and showed upcoming OSA milestones including a limited market release in H2 2026 and full market release in H1 2027, creating a clearer path into the sleep-apnea category even though commercialization is still early [#8-K-2026-05-06].
2026-12-31catalystCore device franchises are funding the next leg of growthHigh impact
Updated 2026 assumptions call for Cardiopulmonary revenue growth of 8.5%-9.5% and Epilepsy revenue growth of 6.0%-7.0%, supported by Essenz placements, consumables demand, implant growth, and price realization; if execution holds, the core business can finance OSA investment without breaking the margin and cash-flow framework [#8-K-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology